175 related articles for article (PubMed ID: 27646813)
1. Evaluation of heparin dosing based on adjusted body weight in obese patients.
Fan J; John B; Tesdal E
Am J Health Syst Pharm; 2016 Oct; 73(19):1512-22. PubMed ID: 27646813
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an Unfractionated Heparin Pharmacy Dosing Protocol for the Treatment of Venous Thromboembolism in Nonobese, Obese, and Severely Obese Patients.
Hosch LM; Breedlove EY; Scono LE; Knoderer CA
Ann Pharmacother; 2017 Sep; 51(9):768-773. PubMed ID: 28511582
[TBL] [Abstract][Full Text] [Related]
3. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
[TBL] [Abstract][Full Text] [Related]
4. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients.
Spruill WJ; Wade WE; Huckaby WG; Leslie RB
Am J Health Syst Pharm; 2001 Nov; 58(22):2143-6. PubMed ID: 11760916
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.
Tsu LV; Dager WE
Pharmacotherapy; 2012 Jan; 32(1):20-6. PubMed ID: 22392825
[TBL] [Abstract][Full Text] [Related]
6. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.
Bauer SR; Ou NN; Dreesman BJ; Armon JJ; Anderson JA; Cha SS; Oyen LJ
Mayo Clin Proc; 2009 Dec; 84(12):1073-8. PubMed ID: 19955244
[TBL] [Abstract][Full Text] [Related]
7. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
Shlensky JA; Thurber KM; O'Meara JG; Ou NN; Osborn JL; Dierkhising RA; Mara KC; Bierle DM; Daniels PR
Vasc Med; 2020 Feb; 25(1):47-54. PubMed ID: 31623539
[TBL] [Abstract][Full Text] [Related]
8. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.
Myzienski AE; Lutz MF; Smythe MA
Pharmacotherapy; 2010 Mar; 30(3):324. PubMed ID: 20180615
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of weight-based dosing of unfractionated heparin in obese children.
Taylor BN; Bork SJ; Kim S; Moffett BS; Yee DL
J Pediatr; 2013 Jul; 163(1):150-3. PubMed ID: 23414664
[TBL] [Abstract][Full Text] [Related]
10. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity.
Barletta JF; DeYoung JL; McAllen K; Baker R; Pendleton K
Surg Obes Relat Dis; 2008; 4(6):748-53. PubMed ID: 18586569
[TBL] [Abstract][Full Text] [Related]
11. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome.
Joncas SX; Poirier P; Ardilouze JL; Carrier N; Fayad T; Farand P
Obesity (Silver Spring); 2013 Sep; 21(9):1753-8. PubMed ID: 23404940
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Compliance with a Weight-based Nurse-driven Heparin Nomogram in a Tertiary Academic Medical Center.
Schurr JW; Stevens CA; Bane A; Culbreth SE; Miller AL; Connors JM; Sylvester KW
Crit Pathw Cardiol; 2018 Jun; 17(2):83-87. PubMed ID: 29768316
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
Rizk E; Wilson AD; Murillo MU; Putney DR
Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
[TBL] [Abstract][Full Text] [Related]
14. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
[TBL] [Abstract][Full Text] [Related]
15. Heparin dosing and therapeutic activated partial thromboplastin times (aPTT) in acute coronary syndrome (ACS).
Westaway KP; Cruickshank M
Aust Crit Care; 2006 Feb; 19(1):6-8, 10-4. PubMed ID: 16544673
[TBL] [Abstract][Full Text] [Related]
16. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service.
Kershaw B; White RH; Mungall D; Van Houten J; Brettfeld S
Arch Intern Med; 1994 May; 154(9):1005-11. PubMed ID: 8179443
[TBL] [Abstract][Full Text] [Related]
17. Unfractionated heparin dosing in obese patients.
George C; Barras M; Coombes J; Winckel K
Int J Clin Pharm; 2020 Apr; 42(2):462-473. PubMed ID: 32140914
[TBL] [Abstract][Full Text] [Related]
18. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
19. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
20. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
